ReviewMolecular pharmaceutics2026
Liver-on-a-Chip (LoC) Models: Case Studies of Academic Platforms and Commercial Products.
Review in Molecular pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmaceutical companies place significant importance on the liver due to its crucial role in numerous biochemical processes, specifically in drug metabolism. This focus has led to significant progress in liver-on-a-chip (LoC) technology, which has proven useful not only in drug development but also in more advanced applications. As a result, elaboration and incorporation of advanced LoC models into preclinical workflows have great potential to decrease R&D expenses and reduce or even replace animal testing, while improving the safety and efficacy of new therapies. To explore this potential, the present review provides an overview of recent academic and commercial LoC models, examines their different designs and cellular compositions, and evaluates the advantages and disadvantages of their complexity. A systematic comparison of these models is then performed, along with a discussion of their current challenges and future perspectives. Ultimately, we hope this review will assist scientists and industry professionals in selecting optimal models and in contributing to future advancements in LoC technology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.